• 1. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 2. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 3. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 4. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 5. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168

Professional Introduction to Compound with CAS No. 293760-29-9 and Product Name: 4-(1-Ethyl-1H-benzimidazol-2-yl)-1,2,5-oxadiazol-3-amine

The compound with the CAS number 293760-29-9 and the product name 4-(1-Ethyl-1H-benzimidazol-2-yl)-1,2,5-oxadiazol-3-amine represents a significant advancement in the field of medicinal chemistry. This heterocyclic compound has garnered considerable attention due to its unique structural features and potential therapeutic applications. The molecular framework of this compound integrates a benzimidazole moiety with a 1,2,5-oxadiazole ring system, which is a configuration that has been increasingly explored for its pharmacological properties.

Recent research in the domain of biologically active heterocycles has highlighted the importance of such fused ring systems in drug discovery. The benzimidazole component is well-known for its presence in numerous pharmacologically active agents, including those used in anticancer and antimicrobial therapies. The 1,2,5-oxadiazole ring, on the other hand, is recognized for its ability to modulate various biological pathways, making it a valuable scaffold for medicinal chemists. The combination of these two moieties in 4-(1-Ethyl-1H-benzimidazol-2-yl)-1,2,5-oxadiazol-3-amine suggests a compound with multifaceted biological activities.

In the context of modern drug development, this compound has been studied for its potential as an inhibitor of key enzymes and receptors involved in various diseases. The ethyl group attached to the benzimidazole ring enhances the lipophilicity of the molecule, which can be crucial for membrane permeability and thus bioavailability. This feature is particularly important in the design of oral administrable drugs, where achieving optimal absorption rates is essential.

One of the most promising areas of research involving 4-(1-Ethyl-1H-benzimidazol-2-yl)-1,2,5-oxadiazol-3-amine is its investigation as a potential anticancer agent. Studies have shown that compounds with similar structural motifs can interact with DNA and inhibit the activity of enzymes such as topoisomerases and kinases, which are critical for cancer cell proliferation. The oxadiazole ring, in particular, has been identified as a key pharmacophore in several experimental chemotherapeutic agents. The presence of this moiety in 4-(1-Ethyl-1H-benzimidazol-2-yl)-1,2,5-oxadiazol-3-amine may contribute to its ability to disrupt cancer cell growth by interfering with essential molecular pathways.

Furthermore, the benzimidazole component of this compound may play a role in its interaction with biological targets. Benzimidazoles are known to bind to proteins and nucleic acids through hydrogen bonding and hydrophobic interactions. This binding affinity makes them suitable candidates for developing small molecule inhibitors that can modulate protein function. In particular, benzimidazole derivatives have been explored for their potential to inhibit enzymes involved in inflammation and immune responses. Given these properties, 4-(1-Ethyl-1H-benzimidazol-2-yl)-1,2,5-oxadiazol-3-amino could be a valuable candidate for further investigation in therapeutic areas such as autoimmune diseases and inflammatory disorders.

The synthesis of this compound involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Advanced synthetic techniques such as palladium-catalyzed cross-coupling reactions have been employed to construct the complex heterocyclic core efficiently. These methods are essential for producing pharmaceutical intermediates that meet stringent quality standards required for preclinical and clinical studies.

From a computational chemistry perspective, molecular modeling studies have been conducted to predict the binding modes of this compound with potential biological targets. These studies utilize sophisticated algorithms to simulate interactions at the atomic level, providing insights into how the molecule might function within a cellular environment. Such computational approaches are increasingly integral to drug discovery pipelines as they can accelerate the identification of promising candidates while reducing experimental costs.

The pharmacokinetic properties of 4-(1-Ethyl-1H-benzimidazol]-2-y]-1(]25-)oxadiaz01l]-3-amino, including its absorption distribution metabolism and excretion (ADME) profile, are critical factors that determine its suitability as a drug candidate. Preliminary studies have indicated that this compound exhibits favorable solubility characteristics, which could enhance its bioavailability upon administration. Additionally, its metabolic stability appears promising, suggesting that it may have an extended half-life in vivo, allowing for less frequent dosing.

In conclusion, 4-(]Etil-lH-benzo[b]midazo[l]-Z-yI)-[I(25-)oxadi[/z01l]-3-amino (CAS No.: 293760299) represents an exciting development in medicinal chemistry with significant potential therapeutic applications. Its unique structural features, combining a benzimidazole moiety with a 125 oxadiazole ring system, make it an attractive candidate for further exploration as an anticancer agent, anti-inflammatory agent, or other therapeutic modalities. As research continues, additional insights into its biological activity and pharmacological profile will be uncovered, paving the way for novel treatments targeting various diseases.

• 5990-96-5(4-[1-(2-methylbenzyl)-1H-benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine)
• 607369-36-8(1,2,5-Oxadiazol-3-amine,4-[1-[2-(1-piperazinyl)ethyl]-1H-imidazo[4,5-c]pyridin-2-yl]-)
• 607368-87-6(4-(1-Ethyl-1H-imidazo4,5-cpyridin-2-yl)-1,2,5-oxadiazol-3-amine)
• 607374-14-1(1,2,5-Oxadiazol-3-amine,4-(3-ethyl-3H-imidazo[4,5-c]pyridin-2-yl)-(9CI))
• 296790-01-7(2-(4-Amino-furazan-3-yl)-benzoimidazol-1-yl-aceticacid)
• 5169-63-1(4-[1-(3-methylbutyl)benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine)
• 607369-33-5(1H-Imidazo[4,5-c]pyridine-1-propanamine,2-(4-amino-1,2,5-oxadiazol-3-yl)-)
• 5564-81-8(1-Propanone,3-phenyl-1-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-)
• 6752-98-3(2-(4-amino-1,2,5-oxadiazol-3(2H)-ylidene)-1-(3,4-dichlorobenzyl)-2H-benzimidazol-1-ium)
• 607369-07-3(1,2,5-Oxadiazol-3-amine,4-[1-(1-methylethyl)-1H-imidazo[4,5-c]pyridin-2-yl]-)